Pharma-Govt Collusion: Trump’s Regeneron Deal Masks Structural Drug Price Crisis, Exacerbating Inequity in U.S. Healthcare

Indigenous epistemologies frame healthcare as a collective right, not a market commodity, challenging the U.S. model of patent-driven exclusivity. Traditional knowledge systems, such as those in the Amazon or Māori traditions, often prioritize plant-based remedies shared openly, contrasting with Regeneron’s proprietary monoclonal antibodies. The absence of Indigenous voices in this narrative reflects a broader erasure of communal health paradigms in favor of extractive pharmaceutical capitalism.

The U.S. drug pricing crisis is rooted in the 1984 Hatch-Waxman Act, which extended patent monopolies and incentivized 'evergreening' of drugs, and the 2003 Medicare Modernization Act, which explicitly banned Medicare from negotiating prices. Historical parallels include the 1990s HIV crisis, where activists forced price reductions through direct action, or the 1960s thalidomide scandal, which led to the Kefauver-Harris Amendments—yet today’s regulatory capture prevents similar reforms. The current deal echoes Nixon-era 'war on cancer' public-private partnerships, which enriched pharmaceuticals while failing to deliver cures.

Globally, nations like Canada, Germany, and Australia cap drug prices through reference pricing or direct negotiation, achieving 30-50% lower costs than the U.S. for the same drugs. In Cuba, biotech innovation is publicly funded and shared internationally, proving that profit motives are not prerequisites for medical advancement. The African Union’s *Pharmaceutical Manufacturing Plan for Africa* (2021) aims to reduce reliance on imports by 70% by 2030, offering a model of regional self-sufficiency. These systems highlight how policy design—not market magic—drives affordability.

Pharmaceutical pricing is not determined by R&D costs (which are often publicly funded) but by patent monopolies and marketing expenditures, which account for 20-30% of revenue. Studies show that the U.S. pays 2-3x more for drugs than peer nations due to lack of price controls, not innovation incentives. Regeneron’s monoclonal antibodies, like many biologics, are priced at $1,500+ per dose despite marginal production costs, reflecting structural rent-seeking rather than scientific value.

Artistic and spiritual traditions often critique commodification of life, from the biblical 'render unto Caesar' to Buddhist teachings on attachment to material wealth. The U.S. healthcare system’s fixation on profit-driven innovation mirrors the Greek myth of Prometheus, where fire (medicine) is hoarded by elites while the masses suffer. Indigenous art, such as the Huichol yarn paintings of Mexico, depicts healing as a sacred, communal act—contrasting with the sterile, transactional ethos of pharmaceutical marketing.

If current trends persist, U.S. drug spending will reach $875 billion by 2030 (25% of total healthcare costs), with 1 in 4 Americans rationing medications due to cost. Scenario modeling suggests that Medicare negotiation (as in the Inflation Reduction Act) could save $100B over a decade, while open-source drug development (e.g., Medicines Patent Pool) could reduce prices by 90% for generics. A future where health is a constitutional right (as in Brazil’s 1988 Constitution) would require dismantling patent monopolies and redirecting R&D toward unmet needs.

Black and Latino communities in the U.S. face 2-3x higher rates of insulin rationing due to cost, with Indigenous populations experiencing 40% higher mortality from treatable conditions like diabetes. Low-income seniors on fixed incomes are forced to choose between medications and groceries, a reality obscured by the 'middle-class' framing of the drug crisis. Immigrant communities, including undocumented workers, are systematically excluded from price negotiation efforts, exacerbating disparities. The deal’s PR focus on 'lower prices' ignores these populations entirely.